Ionis Pharma's TRYNGOLZA Receives FDA Approval For Genetic Disorder Treatment

Ionis Pharmaceuticals Inc. (IONS) announced that the U.S. Food and Drug Administration approved TRYNGOLZA (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis.